Jyong Biotech CEO Fu-Feng Kuo detailed the company's strategy to secure FDA approval for Botreso®, a plant-derived drug aimed at treating benign prostatic hyperplasia (BPH), a condition affecting over 12 million men in the US. The company uses proprietary technologies to enhance drug bioavailability and has completed pivotal studies showing a strong safety profile. Jyong Biotech plans further US pharmacokinetic and Phase III trials, targeting FDA approval by 2029-2030. The company also explores preventative urological care and metabolic disease treatments, prioritizing the US market to leverage regulatory and commercial advantages globally.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
NVIDIA and Noetra Corp. are partnering to build Japan's first national AI infrastructure, the NVIDIA Vera Rubin AI factory, featuring 13,750 Vera CPUs and 27,500 Rubin GPUs. Supported by Japan's Ministry of Economy, Trade and Industry, this 140-megaw...
Flight searches from the UK to destinations along the path of the August 12, 2026 solar eclipse have surged, with increases up to 201% for Spain's Cantabrian Coast and over 100% for Reykjavik, Iceland. This eclipse is notable as the first visible tot...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
